1. Home
  2. MDV vs ENTA Comparison

MDV vs ENTA Comparison

Compare MDV & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDV
  • ENTA
  • Stock Information
  • Founded
  • MDV 2015
  • ENTA 1995
  • Country
  • MDV United States
  • ENTA United States
  • Employees
  • MDV N/A
  • ENTA N/A
  • Industry
  • MDV Transportation Services
  • ENTA Biotechnology: Pharmaceutical Preparations
  • Sector
  • MDV Consumer Discretionary
  • ENTA Health Care
  • Exchange
  • MDV Nasdaq
  • ENTA Nasdaq
  • Market Cap
  • MDV 152.5M
  • ENTA 154.0M
  • IPO Year
  • MDV 2022
  • ENTA 2013
  • Fundamental
  • Price
  • MDV $16.04
  • ENTA $5.59
  • Analyst Decision
  • MDV Strong Buy
  • ENTA Buy
  • Analyst Count
  • MDV 1
  • ENTA 4
  • Target Price
  • MDV $18.00
  • ENTA $17.25
  • AVG Volume (30 Days)
  • MDV 45.1K
  • ENTA 228.9K
  • Earning Date
  • MDV 03-04-2025
  • ENTA 05-05-2025
  • Dividend Yield
  • MDV 7.27%
  • ENTA N/A
  • EPS Growth
  • MDV N/A
  • ENTA N/A
  • EPS
  • MDV 0.25
  • ENTA N/A
  • Revenue
  • MDV $46,907,000.00
  • ENTA $66,590,999.00
  • Revenue This Year
  • MDV $1.68
  • ENTA N/A
  • Revenue Next Year
  • MDV $7.49
  • ENTA N/A
  • P/E Ratio
  • MDV $63.62
  • ENTA N/A
  • Revenue Growth
  • MDV N/A
  • ENTA N/A
  • 52 Week Low
  • MDV $13.69
  • ENTA $4.71
  • 52 Week High
  • MDV $18.11
  • ENTA $17.80
  • Technical
  • Relative Strength Index (RSI)
  • MDV 57.45
  • ENTA 31.66
  • Support Level
  • MDV $15.56
  • ENTA $5.65
  • Resistance Level
  • MDV $16.07
  • ENTA $5.96
  • Average True Range (ATR)
  • MDV 0.58
  • ENTA 0.36
  • MACD
  • MDV 0.02
  • ENTA -0.15
  • Stochastic Oscillator
  • MDV 82.38
  • ENTA 4.77

About MDV Modiv Industrial Inc. Class C

Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The Company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from company's consolidated real estate properties.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Share on Social Networks: